Cmg Pharmaceutical Co., Ltd.

The Asan Foundation

Sungkwang Medical Foundation

Jung Jin Hwang

Eun Kyung Choi

Jeongbeob Seo

Suk Young Cho

Gilnam Lee

Choung Soo Kim

Jin Sung Kim

Albert Charles Gyorkos

Chul Soo Lim

Han Won Cho

Hee Jung An

Hye Sun Jeon

Yong Wha Moon

Jung Shin Lee

Chul Yun Rhim

Ki Joon Jeon

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.

Substituted pyridinone compounds as MEK inhibitors

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3' OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. 

Pyridopyrimidine derivatives and use thereof

Growing community of inventors

Seoul, South Korea

Jung Jin Hwang